Nomination committee appointed for IRLAB’s annual general meeting 2027

Gothenburg, Sweden, October 20, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announces that the nomination committee ahead of the annual general meeting (AGM) 2027 has been appointed.

IRLAB’s Preclinical Research Underpinning Linepemat Published in Peer-Reviewed Journal

IRLAB to present at Redeye Theme: Neurology